U.S. Consumer Services Stock News

NasdaqGS:WING
NasdaqGS:WINGHospitality

Wingstop (WING) Margin Surge To 25.5% Reinforces Bullish Profitability Narrative

Wingstop (WING) just posted its FY 2025 third quarter numbers, reporting revenue of US$175.7 million and basic EPS of US$1.02, while trailing twelve month EPS is US$6.15 on revenue of US$683.0 million. The company’s revenue has moved from US$162.5 million and EPS of US$0.88 in Q3 2024 to US$175.7 million and EPS of US$1.02 in Q3 2025. This sits alongside trailing net income of US$174.3 million, which contributes to the 25.5% net margin reported over the past year and highlights a results...
NasdaqGS:ADI
NasdaqGS:ADISemiconductor

Analog Devices (ADI) Net Margin Expansion Tests Bullish Long‑Term Profitability Narratives

Analog Devices (ADI) opened its new fiscal year with Q1 2026 results that sit on top of a clear ramp in recent quarters, with revenue moving from US$2,443.2 million in Q4 2024 to US$3,076.1 million in Q4 2025 and basic EPS stepping up from US$0.96 to US$1.60 over the same period. Over the trailing twelve months to Q4 2025, total revenue reached US$11.0 billion and basic EPS came in at US$4.59. This gives investors a fuller sense of earnings power coming into this latest print and sets the...
NasdaqGS:ROIV
NasdaqGS:ROIVBiotechs

A Look At Roivant Sciences (ROIV) Valuation After PHocus Trial Milestone And Weak Quarterly Earnings

Clinical and earnings updates shift focus for Roivant Sciences (ROIV) Roivant Sciences (ROIV) shares are in focus after the company reported a key clinical milestone for its pulmonary hypertension program and quarterly results that showed lower sales and a larger net loss compared with last year. See our latest analysis for Roivant Sciences. The clinical milestone and latest earnings are landing against a backdrop of strong momentum, with Roivant Sciences showing a 30 day share price return...
NasdaqGS:MTCH
NasdaqGS:MTCHInteractive Media and Services

Assessing Match Group (MTCH) Valuation As User Metrics Weaken And Board Changes Continue

Board changes and weak user trends put Match Group in focus Match Group (MTCH) is back on investors’ radars after fresh boardroom changes and pressure on its core metrics, with payer counts, average revenue per user, and engagement all weakening over the last two years. See our latest analysis for Match Group. Despite the latest board reshuffle and weaker user metrics, Match Group’s recent share price returns have been slightly negative over most short timeframes, and its 1 year total...
NYSE:HII
NYSE:HIIAerospace & Defense

Huntington Ingalls Taps AI Welding As Investors Weigh Productivity And Valuation

Huntington Ingalls Industries (NYSE:HII) has signed a memorandum of understanding with Path Robotics to integrate AI-driven autonomous welding into shipbuilding operations. The agreement focuses on jointly developing physical AI-based welding systems for use across HII's shipyards. The collaboration aims to automate welding tasks, support the existing workforce, and increase throughput in naval ship production. For a company like Huntington Ingalls Industries, which builds complex naval...
NYSE:TROX
NYSE:TROXChemicals

Tronox Holdings (TROX) Is Down 7.8% After Wider 2025 Losses Despite Maintained Dividend - What's Changed

Tronox Holdings plc has released its fourth-quarter and full-year 2025 results, showing quarterly sales rising to US$730 million but a much larger net loss of US$176 million, and full-year sales slipping to US$2.90 billions alongside a significantly wider US$470 million loss. Despite these deeper losses, the board maintained a cash dividend of US$0.05 per share and confirmed a director’s decision not to seek re-election for time-commitment reasons rather than any disagreement with the...
NYSE:BLCO
NYSE:BLCOMedical Equipment

Bausch + Lomb (BLCO) Loss Narrows To US$28m As Margin Repair Narrative Gains Traction

Bausch + Lomb (NYSE:BLCO) has put out its latest FY 2025 numbers with Q3 revenue of US$1.3b and a basic EPS loss of US$0.08, as investors weigh how far the business has come toward closing the profitability gap. The company has seen quarterly revenue move from US$1.1b in Q1 2025 to US$1.3b in Q3, while basic EPS losses over that stretch ranged from US$0.60 in Q1 to US$0.18 in Q2 and US$0.08 in Q3. This sets up the current update as a check-in on how quickly margins can repair from here. See...
NYSE:RBA
NYSE:RBACommercial Services

RB Global (RBA) Margin Slippage Tests Bullish Multi Year Earnings Growth Narrative

RB Global (RBA) has wrapped up FY 2025 with fourth quarter revenue of US$1.2 billion and basic EPS of US$0.53, alongside net income excluding extra items of US$99.1 million. This sets a clear marker for how the year finished. Across recent periods, the company has seen quarterly revenue range from US$981.8 million in Q3 2024 to US$1.2 billion in Q4 2025, while basic EPS moved between US$0.36 and US$0.56 over that span. This gives investors a concrete view of how the top and bottom lines have...
NYSE:WMK
NYSE:WMKConsumer Retailing

Weis Markets (WMK) Valuation Check After Recent Share Price Momentum

Recent moves in Weis Markets stock Weis Markets (WMK) has caught investor attention after a steady run, with the share price at $72.70 and total return figures that differ sharply between the past month, past 3 months, and recent years. See our latest analysis for Weis Markets. At a share price of $72.70, Weis Markets has seen short term momentum, with a 30 day share price return of 5.38% and a 90 day share price return of 10.86%. The 1 year total shareholder return of 3.45% contrasts with a...
NYSE:DLB
NYSE:DLBSoftware

Is Dolby Laboratories (DLB) Pricing Reflect Its Potential After Multi Year Share Price Slump

If you are wondering whether Dolby Laboratories' current share price reflects its true worth, you are not alone. This article is built to help you frame that question clearly. The stock closed at US$64.82, with returns of 3.7% over the last 30 days but a 20.7% decline over the past year and a 28.0% decline over five years, which may have changed how some investors view its risk and reward trade off. Recent coverage has focused on Dolby Laboratories' role in audio and visual technologies...
NYSE:NET
NYSE:NETIT

Is It Too Late To Consider Cloudflare (NET) After Its Strong Multi Year Share Price Run?

If you are wondering whether Cloudflare's share price still lines up with its underlying worth, this article will walk through what the current numbers say and where valuation checks seem to disagree with the story. At a recent close of US$191.44, Cloudflare's stock has returned 1.1% over the last week, 3.9% over the last month, a 2.3% decline year to date, and 19.2% over the past year, with a very large 3 year gain of 211.4% and a 5 year gain of 150.5%. Recent headlines around Cloudflare...
NasdaqGS:GEHC
NasdaqGS:GEHCMedical Equipment

Is GE HealthCare Technologies (GEHC) Pricing Reflect Its Post Spinoff Potential Today

If you are wondering whether GE HealthCare Technologies is fairly priced today, this article walks through what the current share price might be implying about its underlying value. The stock last closed at US$82.95, with returns of 4.7% over the past week, 1.5% over the past month, a small 0.2% gain year to date, and a 10.2% decline over the past year. These moves may have some investors reassessing the balance between upside potential and risk. Recent attention on GE HealthCare has focused...
NYSE:TNET
NYSE:TNETProfessional Services

TriNet Group (TNET) Is Down 6.0% After Lower 2026 Outlook And Buyback Update – Has The Bull Case Changed?

In February 2026, TriNet Group reported fourth-quarter 2025 revenue of US$1,248 million with a net loss of US$1 million, and full-year 2025 revenue of US$5,010 million with net income of US$155 million, alongside new 2026 guidance and an update on its long-running share repurchase program. The company’s 2026 outlook, which points to lower total revenue of US$4,750 million to US$4,900 million and reduced diluted earnings per share of US$2.15 to US$3.05, raises fresh questions about how its...
NasdaqGM:TMDX
NasdaqGM:TMDXMedical Equipment

FDA Greenlights ENHANCE Heart Trial As TransMedics Valuation Draws Attention

TransMedics Group received full FDA approval for its Next-Generation OCS ENHANCE Heart trial Investigational Device Exemption. The trial is designed to assess the company’s Organ Care System Heart technology for prolonged heart perfusion versus current storage methods. This FDA decision marks a material development for NasdaqGM:TMDX and its organ transplant platform. TransMedics Group, trading on NasdaqGM:TMDX, now has a fresh regulatory green light that adds to its profile in the heart...
NasdaqGS:KRYS
NasdaqGS:KRYSBiotechs

Is Krystal Biotech (KRYS) Priced Right After A 61% One-Year Share Gain?

If you are wondering whether Krystal Biotech's share price reflects its true worth, this article will walk through how the current market price compares with a range of valuation checks. The stock last closed at US$283.29, with returns of 3.9% over 7 days, 14.7% year to date, and 60.8% over the past year. This performance has put it firmly on many investors' radar. Recent interest in Krystal Biotech has been shaped by ongoing attention to its gene therapy pipeline and regulatory milestones...
NYSE:SMWB
NYSE:SMWBSoftware

Similarweb (SMWB) Q4 Loss Widens As Profitability Timeline Faces Bullish Narrative Test

Similarweb (SMWB) has wrapped up FY 2025 with Q4 revenue of US$72.8 million and a basic EPS loss of US$0.09, alongside net income excluding extra items of a US$7.5 million loss. The company has seen revenue move from US$65.6 million in Q4 2024 to US$72.8 million in Q4 2025, while quarterly basic EPS shifted from a US$0.07 loss to a US$0.09 loss over the same period. This sets up a story focused on how quickly margins can tighten or ease from here. See our full analysis for Similarweb. With...
NYSE:DAL
NYSE:DALAirlines

Is It Time To Reassess Delta Air Lines (DAL) After Recent Share Price Moves

If you are wondering whether Delta Air Lines is fairly priced or if the current share price leaves some value on the table, this article will walk you through what the numbers are saying about the stock. Delta’s share price recently closed at US$71.11, with returns of 10.6% over 1 year, 3.0% year to date, 1.0% over 30 days, and a 0.4% decline over the last 7 days. These figures may hint at shifting views on its growth prospects and risk. Recent headlines around Delta have focused on broader...
NYSE:MCO
NYSE:MCOCapital Markets

Moody's (MCO) Margin Strength Reinforces Bullish Narratives Despite Premium Valuation Concerns

Moody's (MCO) has just posted third quarter FY 2025 revenue of US$2.0b and basic EPS of US$3.61, with trailing twelve month revenue at US$7.5b and EPS at US$12.48 framing the latest print within a larger earnings run rate. The company has seen quarterly revenue move from US$1.82b in Q2 2024 to US$1.90b in Q2 2025 and then US$2.01b in Q3 2025, while basic EPS moved from US$3.03 to US$3.22 and then US$3.61 over the same quarters, giving investors a clear view of how the income statement is...
NasdaqGS:GSHD
NasdaqGS:GSHDInsurance

Goosehead Insurance (GSHD) Margin Compression Challenges Bullish Earnings Growth Narratives

Goosehead Insurance (GSHD) closed FY 2025 with fourth quarter revenue of US$105.3 million and basic EPS of US$0.50, alongside trailing twelve month revenue of US$365.3 million and EPS of US$1.11 that frame the latest print in a wider context of reported earnings. Over the past six quarters, revenue has moved from US$77.8 million in Q3 2024 to US$105.3 million in Q4 2025, while quarterly EPS has ranged from US$0.09 in Q1 2025 to US$0.60 in Q4 2024. This gives investors a clearer view of how...
NYSE:DBD
NYSE:DBDTech

Diebold Nixdorf (DBD) Is Up 11.5% After Buybacks And Swing To Profitability Amid Arena Exit

In February 2026, Diebold Nixdorf reported that it had completed two share repurchase programs totaling 2,307,275 shares for US$150.57 million and announced fourth-quarter 2025 net income of US$49.6 million, with full-year 2025 net income of US$94.6 million following a loss a year earlier. At the same time, Arena Capital Advisors fully exited its roughly US$35 million position, meaning improved profitability and capital returns are unfolding alongside a complete withdrawal by one of the...
NYSE:FVRR
NYSE:FVRRProfessional Services

Fiverr (FVRR) Earnings Growth And 5.2% Margin Test Bullish Profitability Narrative

Fiverr International (FVRR) just posted its FY 2025 numbers with Q3 revenue of US$107.9 million and basic EPS of US$0.15, set against trailing twelve month revenue of US$427.4 million and EPS of US$0.62 that reflect earnings growth of 121.2% over the past year. The company has seen quarterly revenue move from US$94.7 million in Q2 2024 to a range of roughly US$107 million to US$108.6 million across the first three quarters of 2025. Over the same 2025 periods, basic EPS shifted from US$0.09 in...
NasdaqGS:TRIP
NasdaqGS:TRIPInteractive Media and Services

Starboard Targets Tripadvisor Board As Activism Meets AI And Experiences Story

Starboard Value has launched an activist campaign targeting Tripadvisor's board, seeking to replace a majority of directors. The investor is urging Tripadvisor to consider options to maximize shareholder value, including a possible sale of the company. Starboard has criticized Tripadvisor's strategic direction, use of Generative AI, and past decisions it views as unfavorable to shareholders. For anyone tracking NasdaqGS:TRIP, this campaign comes after a challenging stretch for the stock...
NasdaqGS:IDYA
NasdaqGS:IDYABiotechs

IDEAYA Biosciences (IDYA) Q4 Loss Of US$83.3 Million Tests Bullish Growth Narrative

IDEAYA Biosciences (IDYA) has wrapped up FY 2025 with Q4 revenue of US$10.9 million, a basic EPS loss of US$0.94, and net income excluding extra items at a loss of US$83.3 million. Trailing twelve month figures show revenue of US$218.7 million and a basic EPS loss of US$1.28. Over recent quarters, the company’s revenue moved from US$7.0 million in Q4 2024 to US$207.8 million in Q3 2025 before landing at US$10.9 million in Q4 2025. Basic EPS ranged from a loss of US$1.49 in Q4 2024 to a profit...
NasdaqGS:ALGM
NasdaqGS:ALGMSemiconductor

A Look At Allegro MicroSystems (ALGM) Valuation After Upgrade, New Sensor Launch And Earnings Beat

Morgan Stanley’s recent upgrade of Allegro MicroSystems (ALGM), paired with earnings that topped expectations, has focused attention on how the new ACS37017 current sensor and leadership changes could shape the stock’s risk reward profile. See our latest analysis for Allegro MicroSystems. The recent 1 day share price decline of 7.44% and 7 day share price return of negative 9.86% sit against a stronger backdrop, with a 90 day share price return of 69.25% and 1 year total shareholder return of...